Drugs / ORB-021
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06607939 | Nov 2024 → May 2026 overdue | — | Orionis Biosciences Inc | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORB-021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06607939 ↗ |
| Action | Activate | “confers full activity to individual cells when also bound to the target” NCT06607939 ↗ |
| Modality | Protein / enzyme biologic | “ORB-021 is a complex engineered biologic molecule” NCT06607939 ↗ |
| Route | Intravenous | “ORB-021 is administered by intravenous (IV) infusion/injection” NCT06607939 ↗ |